Physician profile
Richa Gupta
NPI 1942466842
$11,182.90
in general payments reported to CMS, 2019-2025
32 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $1,123 · 2021: $1,170 · 2022: $1,096 · 2023: $1,694 · 2024: $1,962 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,768 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,767.82 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,327.74 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,728.84 | 2019-2025 | |
| Pfizer INC. | $1,104.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $989.03 | 2019-2025 | |
| Ucb, INC. | $806.03 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $742.77 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $737.82 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $450.01 | 2019-2025 | Orencia |
| Lilly USA, LLC | $423.70 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $422.84 | 2021-2025 | Saphnelo, Evusheld |
| Aurinia Pharma U.S., INC. | $178.19 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $120.80 | 2023-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $115.67 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $108.13 | 2024 | Arcalyst |
| Genentech USA, INC. | $105.82 | 2019-2024 | Actemra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $96.88 | 2019-2020 | |
| Antares Pharma, INC. | $86.60 | 2019-2020 | |
| Organon LLC | $83.34 | 2024-2025 | Hadlima |
| Actelion Pharmaceuticals US, INC. | $73.95 | 2020-2023 | Uptravi |
| Fresenius Kabi USA, LLC | $69.76 | 2023-2024 | Idacio |
| Ani Pharmaceuticals, INC. | $68.21 | 2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $50.86 | 2023-2025 | |
| Medexus Pharma, INC. | $50.22 | 2019-2021 | |
| Invivyd INC | $44.95 | 2025 | Pemgarda |
| Orthogenrx INC. | $39.67 | 2019 | |
| Celgene Corporation | $33.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.69 | 2020-2022 | |
| Daiichi Sankyo INC. | $20.52 | 2024 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $18.99 | 2024 | Crysvita |
| Sobi, INC | $18.61 | 2022 | |
| Horizon Therapeutics Plc | $17.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.